Novel D-ring analog of epigallocatechin-3-gallate inhibits tumor growth and VEGF expression in breast carcinoma cells
- PMID: 15816564
Novel D-ring analog of epigallocatechin-3-gallate inhibits tumor growth and VEGF expression in breast carcinoma cells
Abstract
The cancer chemopreventive activity of green tea and its major polyphenolic constituent, epigallocatechin-3-gallate (EGCG) have been attributed to its antioxidant, antiproliferative and antiangiogenic effects. Several new molecular targets for EGCG's anticarcinogenic activity have been proposed in the recent literature. However, the understanding of the molecular mechanisms of EGCG's activity in vivo have been confounded by its low oral bioavailability and low plasma levels. Studies of EGCG would be greatly aided by the availability of synthetic analogs of EGCG designed to understand the contributions of the A, B, and D-rings and the phenolic hydroxyl groups of EGCG to its molecular mechanisms of action. We recently reported the de novo synthesis of a D-ring analog of EGCG, with the objective of using such analogs to understand the molecular mechanisms of EGCG action. We report here the first studies with a synthetic D-ring analog of EGCG. We examined the ability of the synthetic D-ring analog to inhibit tumor cell proliferation in breast carcinoma cells. We also investigated the effect of the analog on stress-induced VEGF production in breast carcinoma cells using Northern analysis and quantitative RT-PCR. We report here that the synthetic D-ring analog inhibits breast cancer cell growth in vitro with potencies equivalent to those of EGCG. Our results also show that, like EGCG, the synthetic analog inhibits hypoxia- and serum starvation-induced production of VEGF mRNA in breast cancer cells. Such synthetic analogs are valuable for understanding the structure-function relationship of EGCG and identifying relevant mechanisms of the chemopreventive action of EGCG.
Similar articles
-
Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression.Int J Oncol. 2007 Oct;31(4):705-11. Int J Oncol. 2007. PMID: 17786300
-
Epigallocatechin-3-gallate inhibits the PDGF-induced VEGF expression in human vascular smooth muscle cells via blocking PDGF receptor and Erk-1/2.Int J Oncol. 2006 Nov;29(5):1247-52. Int J Oncol. 2006. PMID: 17016658
-
Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer.Life Sci. 2006 Nov 17;79(25):2329-36. doi: 10.1016/j.lfs.2006.07.036. Epub 2006 Aug 5. Life Sci. 2006. PMID: 16945390 Review.
-
Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo.Cancer Lett. 2007 Jan 8;245(1-2):232-41. doi: 10.1016/j.canlet.2006.01.027. Epub 2006 Mar 6. Cancer Lett. 2007. PMID: 16519995
-
Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate.Cancer Res. 2006 Mar 1;66(5):2500-5. doi: 10.1158/0008-5472.CAN-05-3636. Cancer Res. 2006. PMID: 16510563 Review.
Cited by
-
Cancer Chemoprevention by Phytochemicals: Nature's Healing Touch.Molecules. 2017 Mar 3;22(3):395. doi: 10.3390/molecules22030395. Molecules. 2017. PMID: 28273819 Free PMC article. Review.
-
Chemoprevention of head and neck cancer with green tea polyphenols.Cancer Prev Res (Phila). 2010 Aug;3(8):900-9. doi: 10.1158/1940-6207.CAPR-09-0131. Epub 2010 Jul 27. Cancer Prev Res (Phila). 2010. PMID: 20663981 Free PMC article. Review.
-
Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise.Arthritis Res Ther. 2010;12(2):208. doi: 10.1186/ar2982. Epub 2010 Apr 28. Arthritis Res Ther. 2010. PMID: 20447316 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical